PMID- 19895711
OWN - NLM
STAT- MEDLINE
DCOM- 20100104
LR  - 20211020
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 7
DP  - 2009 Nov 9
TI  - Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization 
      (FISH) assessment for Her-2 status in breast cancer.
PG  - 83
LID - 10.1186/1477-7819-7-83 [doi]
AB  - BACKGROUND: The concordance rate between IHC and FISH according to clinical 
      performance is still controversial. We report a prospective study to reflect the 
      concordance between IHC and FISH in Guilin city, People's Republic of China. 
      METHODS: Fifty cases of invasive ductal carcinoma of breast tested by IHC and 
      scored as 0, 1+, 2+ and 3+ by pathologists were further analyzed by FISH using a 
      commercially available double-color probe, and the FISH findings were compared 
      with IHC test results. RESULTS: A total concordance of 82.0% was observed with a 
      Kappa coefficient of 0.640 (P<0.001). A high discordance was observed in 30.0% of 
      the patients with IHC 2+, 7.1% in IHC 3+, 19.2% overall in IHC 0 and 1+. 
      CONCLUSION: The IHC can be used firstly to screen the HER-2 status, and FISH can 
      be used as a supplementary role to IHC and 2+ and some negative cases. And only 
      those cases with Her-2 status of IHC 3+ or FISH positive should be treated with 
      Herceptin.
FAU - Sui, Weiguo
AU  - Sui W
AD  - Laboratory Center of Guangzhou Military Area Command, 181st Hospital of People's 
      Liberation Army, and College of Life Science, Guangxi Normal University, Guilin, 
      Guangxi, PR China. suiwg@163.com
FAU - Ou, Minglin
AU  - Ou M
FAU - Chen, Jiejing
AU  - Chen J
FAU - Wan, Youhua
AU  - Wan Y
FAU - Peng, Hongbo
AU  - Peng H
FAU - Qi, Minfang
AU  - Qi M
FAU - Huang, He
AU  - Huang H
FAU - Dai, Yong
AU  - Dai Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091109
PL  - England
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/genetics/*metabolism
MH  - Carcinoma, Ductal, Breast/genetics/metabolism
MH  - China
MH  - Female
MH  - Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - *Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Receptor, ErbB-2/*metabolism
MH  - Reproducibility of Results
MH  - Tissue Fixation
PMC - PMC2776594
EDAT- 2009/11/10 06:00
MHDA- 2010/01/05 06:00
PMCR- 2009/11/09
CRDT- 2009/11/10 06:00
PHST- 2009/08/30 00:00 [received]
PHST- 2009/11/09 00:00 [accepted]
PHST- 2009/11/10 06:00 [entrez]
PHST- 2009/11/10 06:00 [pubmed]
PHST- 2010/01/05 06:00 [medline]
PHST- 2009/11/09 00:00 [pmc-release]
AID - 1477-7819-7-83 [pii]
AID - 10.1186/1477-7819-7-83 [doi]
PST - epublish
SO  - World J Surg Oncol. 2009 Nov 9;7:83. doi: 10.1186/1477-7819-7-83.